Patents by Inventor Mathew Calder

Mathew Calder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase
    Patent number: 10538524
    Abstract: This invention relates to compounds of formula (I). The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: January 21, 2020
    Assignee: Loxo Oncology Inc.
    Inventors: Mathew Calder, Nicolas Guisot
  • Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase
    Publication number: 20190119281
    Abstract: This invention relates to compounds of formula (I). The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: May 11, 2018
    Publication date: April 25, 2019
    Inventors: Mathew Calder, Nicolas Guisot
  • Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase
    Patent number: 9975897
    Abstract: This invention relates to compounds of formula (I). The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: May 22, 2018
    Assignee: Loxo Oncology, Inc.
    Inventors: Mathew Calder, Nicolas E. S. Guisot
  • Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase
    Publication number: 20170129897
    Abstract: This invention relates to compounds of formula (I). The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: June 11, 2015
    Publication date: May 11, 2017
    Inventors: Mathew Calder, Nicolas E.S. Guisot